natgillin/translations-raw huggingface dataset:
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Quinsair's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Quinsair večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Other information about Quinsair 
Druge informacije o zdravilu Quinsair
In addition, the company that markets Quinsair will carry out a study to investigate the long-term safety of Quinsair when used in clinical practice in the European Union. 
Poleg tega bo družba, ki trži zdravilo Quinsair, izvedla študijo, v kateri bodo raziskali njegovo dolgoročno varnost pri uporabi v klinični praksi v Evropski uniji.
Because levofloxacin has a potential risk on cartilage, the use of the product was not considered justified in adolescents. 
Ker pri uporabi levofloksacina obstaja tveganje za učinke na hrustanec, je bilo ocenjeno, da njegova uporaba pri mladostnikih ni upravičena.
Levofloxacin is a well-known antibiotic. 
Levofloksacin je dobro znan antibiotik.
The most common side effects with Quinsair are cough (seen in 54% of patients), dysgeusia (taste disturbances, 30%) and tiredness/weakness (25%). 
Najpogostejši neželeni učinki zdravila Quinsair so kašelj (opažen pri 54 % bolnikov), disgevzija (motnje okušanja, pri 30 %) in utrujenost/šibkost (25 %).
A risk management plan has been developed to ensure that Quinsair is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Quinsair je bil pripravljen načrt obvladovanja tveganj.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Quinsair, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The second study showed that Quinsair was at least as good as tobramycin at improving FEV1 following 1 to 3 treatment cycles. 
Druga študija je pokazala, da je bilo zdravilo Quinsair vsaj tako učinkovito kot tobramicin pri izboljšanju FEV1 po enem do treh ciklusih zdravljenja.
The first study, which involved 330 patients, compared Quinsair with placebo (a dummy treatment), while the second, involving 282 patients, compared it with another inhaled antibiotic (tobramycin). 
V prvi študiji, v kateri je sodelovalo 330 bolnikov, so zdravilo Quinsair primerjali s placebom (zdravilom brez zdravilne učinkovine), v drugi, v kateri je sodelovalo 282 bolnikov, pa so ga primerjali z drugim antibiotikov za inhaliranje (tobramicinom).
Following 28 days of treatment, the patients taking Quinsair had an improvement in FEV1 of 1.73%, while for patients taking placebo the improvement in FEV1 was of around 0.43%. 
Po 28 dneh zdravljenja se je FEV1 pri bolnikih, ki so uporabljali zdravilo Quinsair, izboljšal za 1,73 %, pri bolnikih, ki so uporabljali placebo, pa za približno 0,43 %.
What benefits of Quinsair have been shown in studies? 
Kakšne koristi je zdravilo Quinsair izkazalo v študijah?
What are the risks associated with Quinsair? 
Kakšna tveganja so povezana z zdravilom Quinsair?
For more information about treatment with Quinsair, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Quinsair preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is Quinsair and what is it used for? 
Kaj je zdravilo Quinsair in za kaj se uporablja?
Why is Quinsair approved? 
Zakaj je bilo zdravilo Quinsair odobreno?
Cystic fibrosis is an inherited disease in which there is an accumulation of thick mucus in the lungs that allows bacteria to grow more easily, causing infections. 
Cistična fibroza je dedna bolezen, pri kateri se v pljučih kopiči gosta sluz, ki omogoča lažjo rast bakterij, kar povzroča okužbe.
Before using Quinsair, doctors should consider official guidance on the appropriate use of antibiotics. 
Preden zdravnik predpiše zdravilo Quinsair, mora pretehtati njegovo uporabo glede na uradne smernice za ustrezno uporabo antibiotikov.
It works by blocking enzymes that P. aeruginosa bacteria use to make copies of their DNA during cell multiplication. 
Deluje tako, da zavira encime, s pomočjo katerih bakterije P. aeruginosa med celičnim razmnoževanjem izdelajo kopije DNK.
For the full list of all side effects reported with Quinsair, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Quinsair, glejte navodilo za uporabo.
The active substance in Quinsair, levofloxacin, belongs to the group of antibiotics known as ‘fluoroquinolones'. 
Zdravilna učinkovina v zdravilu Quinsair, levofloksacin, spada v skupino antibiotikov, imenovanih „fluorokinoloni“.
The CHMP considered that the modest improvement in FEV1 seen with Quinsair meant that it could help to meet the need for additional inhaled antibiotics to treat long-term P. aeruginosa infections in cystic fibrosis. 
Menil je, da majhno izboljšanje FEV1, ki so ga opazili pri uporabi zdravila Quinsair, pomeni, da bi zdravilo lahko pomagalo izpolniti potrebe po dodatnih antibiotikih za inhaliranje za zdravljenje dolgotrajnih okužb z bakterijo P. aeruginosa pri bolnikih s cistično fibrozo.
For practical information about using Quinsair, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Quinsair naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
By doing this, it stops the bacteria that are causing the infection from growing and multiplying. 
Tako ustavi rast in razmnoževanje bakterij, ki povzročajo okužbo.
Regarding safety, Quinsair was well tolerated with side effects similar to those of levofloxacin given systemically (throughout the body). 
Kar zadeva varnost, so bolniki zdravilo Quinsair dobro prenašali, neželeni učinki pa so bili podobni neželenim učinkom levofloksacina za sistemsko uporabo (ki deluje na celotno telo).
However, the study failed to show that Quinsair is more effective than placebo at increasing the time it took before the patients had an exacerbation (flare-up) of their disease. 
Na drugi strani v študiji niso uspeli dokazati, da je zdravilo Quinsair učinkovitejše od placeba pri podaljšanju časa do eksacerbacije (poslabšanja) bolezni pri bolnikih.
It is not intended to provide practical advice on how to use Quinsair. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Quinsair is an antibiotic used for treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in adults who have cystic fibrosis. 
Zdravilo Quinsair je antibiotik, ki se uporablja za zdravljenje dolgotrajne okužbe pljuč z bakterijo Pseudomonas aeruginosa pri odraslih, ki imajo cistično fibrozo.
Quinsair must not be used in patients with epilepsy and those with a history of tendon disorders related to the use of fluoroquinolone antibiotics. 
Zdravilo Quinsair se ne sme uporabljati pri bolnikih z epilepsijo in pri tistih, ki so že kdaj imeli težave s kitami, povezane z uporabo fluorokinolonskih antibiotikov.
Quinsair has been investigated in two main studies in patients who had cystic fibrosis with P. aeruginosa lung infection. 
Zdravilo Quinsair so raziskali v dveh glavnih študijah, v katerih so sodelovali bolniki s cistično fibrozo in okužbo pljuč z bakterijo P. aeruginosa.
In the first study, Quinsair was shown to be better than placebo at improving the patients' forced expiratory volume in one second (FEV1), adjusted for the patient's age, height and sex. FEV1 is the most air a person can breathe out in one second. 
Prva študija je pokazala, da je bilo zdravilo Quinsair boljše od placeba pri izboljšanju forsiranega ekspiracijskega volumna bolnikov v eni sekundi (FEV1), pri čemer so rezultate prilagodili glede na bolnikovo starost, višino in spol.
Quinsair is available as a nebuliser solution in single-dose containers called ‘ampoules'. 
Zdravilo Quinsair je na voljo v obliki raztopine za nebulator v enoodmernih vsebnikih, imenovanih „ampule“.
Quinsair is inhaled using a device called Zirela nebuliser system, which converts the solution in the ampoule into a fine mist. 
Zdravilo Quinsair se inhalira s pomočjo nebulatorskega sistema Zirela, ki raztopino v ampuli pretvori v fino meglico.
Quinsair contains the active substance levofloxacin. 
Zdravilo Quinsair vsebuje zdravilno učinkovino levofloksacin.
How does Quinsair work? 
Kako zdravilo Quinsair deluje?
How is Quinsair used? 
Kako se zdravilo Quinsair uporablja?
Ref.: EMEA/CHMP/730064/2009 
: EMA/730064/2009 EMEA/H/C/997
The main measure of effectiveness was the change in ‘clinical attachment level' (CAL) after 24 weeks. 
Glavno merilo učinkovitosti je bila sprememba „klinične ravni pritrjenosti“ (CAL) po 24 tednih.
Questions and answers on the recommendation for the refusal of the marketing authorisation for Gemesis 
Vprašanja in odgovori v zvezi s priporočilom za zavrnitev vloge za dovoljenje za promet z zdravilom Gemesis bekaplermin
The CHMP was also concerned about the level of product-related impurities present. 
CHMP je bil zaskrbljen tudi zaradi ravni nečistot, prisotnih v izdelku.
The effects of Gemesis were first tested in experimental models before being studied in humans. 
Učinki zdravila Gemesis so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
In one main study involving 180 adults with advanced periodontal disease, Gemesis was compared with the matrix alone. 
V eni glavni študiji, v kateri je sodelovalo 180 odraslih z napredovalo periodontalno boleznijo so zdravilo Gemesis primerjali z matrico.
On 23 July 2009, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Gemesis, intended for bone and periodontal (around the teeth) regeneration in adults. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je v svojem negativnem mnenju z dne 23. julija 2009 priporočil zavrnitev vloge za dovoljenje za promet z zdravilom Gemesis, namenjenim kostni in periodontalni (področju okrog zob) regeneraciji pri odraslih.
Becaplermin is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human platelet-derived growth factor. 
Bekaplermin se izdeluje z metodo, znano kot „tehnologija rekombinantne DNK“: izdela ga celica, ki je prejela gen (DNK), s katerim lahko tvori človeški rastni faktor iz trombocitov.
The company that applied for authorisation is BioMimetic Therapeutics Ltd. 
Vlogo za dovoljenje je predložila družba BioMimetic Therapeutics Ltd.
What are the consequences of the refusal for patients in clinical trials or compassionate use programmes using Gemesis? 
Kakšne so posledice zavrnitve za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Gemesis?
Therefore, at that point in time, the CHMP was of the opinion that the benefits of Gemesis did not outweigh its risks. 
Zato je bil CHMP v tem času mnenja, da koristi zdravila Gemesis ne presegajo z njim povezanih tveganj.
Growth factors are proteins that stimulate cells to multiply. 
Rastni faktorji so beljakovine, ki spodbujajo razmnoževanje celic.
The CHMP was of the opinion that the main study failed to show that Gemesis was effective in treating periodontal defects. 
CHMP je menil, da glavna študija ni dokazala učinkovitosti zdravila Gemesis pri zdravljenju periodontalnih težav.
The active substance in Gemesis, becaplermin, is a recombinant human platelet-derived growth factor (PDGF). 
Zdravilna učinkovina v zdravilu Gemesis, bekaplermin, je rekombinantni človeški rastni faktor iz trombocitov (PDGH).
The CHMP refusal was confirmed after re-examination. 
Zavrnitev je bila po ponovni presoji mnenja potrjena.
The kit consists of a prefilled syringe containing the active substance becaplermin and a cup containing granules of β-tricalcium phosphate to be used as a matrix. 
Sestavljen je iz prednapolnjene brizge, ki vsebuje zdravilno učinkovino bekaplermin, in skodelico z zrnci β-trikalcijevega fosfata, ki se uporablja kot matrica.
What was Gemesis expected to be used for? 
Za kaj naj bi se zdravilo Gemesis uporabljalo?
What is Gemesis? 
Kaj je zdravilo Gemesis?
CAL is a measure of the loss of support to the teeth from surrounding tissue. 
CAL je merilo za izgubo opore, ki jo zobu ponuja tkivo, s katerim je obdan.
Becaplermin was expected to work in the same way as human platelet-derived growth factor, stimulating cell growth in the bone and gums around the teeth and helping tissue to heal. 
Bekaplermin naj bi deloval enako kot človeški rastni faktor iz trombocitov, torej naj bi spodbujal rast celic v kosteh in dlesnih okoli zob in pospešil celjenje tkiva.
Hence, the CHMP recommended that Gemesis be refused marketing authorisation. 
CHMP je zato priporočil zavrnitev dovoljenja za promet z zdravilom Gemesis.
The company informed the CHMP that there are no patients in clinical trials or compassionate use programmes using Gemesis. 
Družba je obvestila CHMP, da klinična preskušanja ali programi sočutne uporabe z zdravilom Gemesis ne potekajo.
Platelet-derived growth factors act on cells that are involved in wound repair. 
Rastni faktorji iz trombocitov delujejo na celice, ki sodelujejo pri celjenju ran.
Gemesis was expected to be used to regenerate tissue in adults with defects around the teeth, including defects within the surrounding bone and receding gums. 
Zdravilo Gemesis naj bi se uporabljalo pri odraslih za regeneracijo obolelega tkiva z nepravilnostmi okrog zob, vključno s težavami na bližnjih kosteh in umikajočimi se dlesnimi.
Gemesis is a kit for implant. 
Zdravilo Gemesis je komplet za vsaditev.
Gemesis was to be prepared by mixing the solution containing becaplermin with the matrix, which was then to be placed into the defect around the teeth to promote healing. 
Zdravilo Gemesis naj bi se pripravilo tako, da se zmešata raztopina, ki vsebuje bekaplermin, in matrica, kar naj bi se položilo na težavno mesto okoli zoba in tako pospešilo celjenje.
How was Gemesis expected to work? 
Kako naj bi zdravilo Gemesis delovalo?
The CHMP noted that the company did not at this time have sufficient information on how strongly becaplermin binds to PDGF receptors and did not sufficiently demonstrate that Gemesis used in clinical studies was comparable to the product intended to be placed on the market. 
CHMP je ugotovil tudi, da družba v danem trenutku ni imela dovolj informacij o tem, kako močno se bekaplermin veže na receptorje rekombinantnega človeškega rastnega faktorja iz trombocitov, ter da ni v zadostni meri prikazala, da je zdravilo Gemesis,
300 mg Powder for concentrate for solution for infusion 
300 mg prašek za koncentrat za raztopino za infundiranje
Vial (glass) 
Intravenska uporaba viala (steklo)
Immediate Packaging 
Sitčna ovojnina Velikost pakiranja
Do not freeze. 
Ne zamrznite.
MARKETING AUTHORISATION NUMBER(S) EU/1/98/093/002 
ŠTEVILKA DOVOLJENJA ZA PROMET EU/1/98/093/002
Boonton, New Jersey 07005 USA 
Boonton, New Jersey 07005 ZDA
Very common ( >1/10); common (>1/100, <1/10); uncommon (>1/1,000, < 1/100); rare (>1/10,000, < 1/1,000); very rare (<1/10,000), including isolated reports. 
Zelo pogosti (>1/10); pogosti (>1/100, <1/10); občasni (>1/1.000, <1/100); redki (>1/10.000, <1/1.000); zelo redki (<1/10.000), vključno s posameznimi primeri.
Each pack contains 10 ampoules. 
Vsaka škatla vsebuje 10 ampul.
The injection will be given to you by a doctor or a nurse. 
Injekcijo vam bo dal zdravnik ali medicinska sestra.
Date of last renewal: 
Datum zadnjega podaljšanja:
The same applies to patients with altered hepatic function. 
Isto velja tudi za bolnike s spremenjeno jetrno funkcijo.
Other possible but less frequent undesirable effects are: 
Drugi možni, vendar manj pogosti, neželeni učinki so:
However, the clinical relevance of this finding is not known. 
Vendar pa klinična pomembnost te ugotovitve ni znana.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorization: 11-01-1999 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve pridobitve: 11. 1. 1999
• swelling of the tongue or throat 
• otekanje jezika ali grla,
• metallic taste in the mouth 
• kovinski okus v ustih,
These are not allergic reactions but are due to a pharmacological effect, and are usually observed 10 to 20 minutes after administration. 
Ne gre za alergične reakcije, temveč za farmakološke učinke, ki se običajno vidijo 10 do 20 minut po uporabi zdravila.
Please ask him to explain the reasons for any changes in your treatment schedule. 
Prosite ga, naj vam razloži, kaj je vzrok za morebitne spremembe v vašem načrtu zdravljenja.
Again, this effect disappears with time, usually during the first or second week of treatment. 
Tudi ta učinek sčasoma izgine, ponavadi v prvem ali drugem tednu zdravljenja.
Any unused product or waste material should be disposed of in accordance with local requirements. 
Neporabljena zdravila ali odpadne snovi je treba zavreči v skladu z lokalnimi zahtevami.
If you forget to inject your medicine at the correct time, inject it as soon as you remember unless it is almost time for the next dose. 
Če si pozabite injicirati zdravilo ob pravem času, storite to takoj, ko se na to spomnite, razen če ni že skoraj čas za naslednji odmerek.
Salmon calcitonin is rapidly absorbed and eliminated. 
Lososov kalcitonin se hitro absorbira in izloči.
Plasma protein binding is 30 to 40%. 
Vezava kalcitonina na plazemske proteine je 30 %-40 %.
Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). 
Biorazpoložljivost po subkutanem in intramuskularnem injiciranju pri ljudeh je visoka in podobna pri obeh načinih dajanja (71 % pri prvem in 66 % pri drugem).
Using FORCALTONIN with other medicines: 
Uporaba FORCALTONINA skupaj z drugimi zdravili:
• anaphylactic shock (a very severe type of allergic response) 
• anafilaktični šok (zelo hud tip alergijske reakcije).
If you are pregnant, please tell your doctor. 
Če ste noseči, seznanite s tem svojega zdravnika.
All of these undesirable effects are mild and occur in isolated cases only. 
Vsi ti neželeni učinki so blagi in se pojavljajo samo v nekaterih primerih.
The only serious undesirable effect which has been reported in patients treated with salmon calcitonin is an allergic reaction. 
Edini resni neželeni učinek, o katerem so poročali pri bolnikih, zdravljenih z lososovim kalcitoninom, je alergijska reakcija.
You should discuss the possible undesirable effects with your doctor who will be able to advise you on the risks and benefits of your treatment. 
O morebitnih neželenih učinkih se pogovorite z zdravnikom, ki vam bo znal svetovati glede tveganj in prednosti zdravljenja.
Conventional long-term toxicity, reproduction, mutagenicity, and carcinogenicity studies have been performed in laboratory animals. 
Običajne študije dolgoročne toksičnosti, reprodukcije, mutagenosti in karcinogenosti so bile opravljene na laboratorijskih živalih.
The pharmacological properties of the synthetic and recombinant peptides have been demonstrated to be qualitatively and quantitatively equivalent. 
Farmakološke lastnosti sintetičnih in rekombinantnih peptidov so se izkazale za kvalitativno in kvantitativno enakovredne.
This is considered a species-specific effect and of no clinical relevance. 
Gre za vrstno specifični učinek brez klinične pomembnosti.
• difficulties in breathing (bronchospasm) 
• težave z dihanjem (bronhospazem),
Dosage is to be adjusted to the individual patient's needs. 
Odmerke moramo prilagajati individualnim potrebam bolnikov.
This medicine has been prescribed for you personally and you should not pass it on to others. 
- Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
The metabolites lack the specific biological activity of calcitonin. 
Metaboliti nimajo specifične biološke aktivnosti kalcitonina.
The presence of antibodies appears to bear no relationship to allergic reactions, which are rare. 
Kaže, da prisotnost protiteles ni povezana z alergijskimi reakcijami, ki so redke.
Never change the dose yourself or stop injecting the medicine without consulting your doctor first. 
Sami nikoli ne smete spreminjati odmerkov ali nehati jemati zdravilo, ne da bi se prej posvetovali z zdravnikom.
Your body's response to treatment will be tested at regular intervals and your doctor will decide whether your treatment needs to be continued and which dose should be used. 
Odziv vašega telesa na zdravilo bodo ugotavljali v rednih časovnih presledkih in vaš zdravnik bo odločil, ali je treba zdravljenje nadaljevati ter s kolikšnim odmerkom.
Calcitonin is indicated for: 
Kalcitonin je indiciran:
Such reactions should be differentiated from generalised or local flushing, which are common non-allergic effects of calcitonin (see 4.8). 
Take reakcije moramo razlikovati od splošnih ali lokalnih rdečic, ki so običajni nealergijski učinek kalcitonina (glejte poglavje 4.8).
In this case, you should wait until it is time to inject the next dose and then continue as before. 
V tem primeru svetujemo, da počakate do injiciranja naslednjega odmerka, potem pa nadaljujte kot običajno.
This effect is diminished as osteoclastic activity is reduced. 
Ta učinek se zmanjša z zmanjšanjem aktivnosti osteoklastov.
You should also talk to your doctor if you feel that the effect of FORCALTONIN is decreasing or that you are no longer benefiting from treatment. 
Zdravniku morate prav tako povedati, če se vam zdi, da se učinek FORCALTONINA zmanjšuje ali da vam zdravljenje ne koristi več.
The effect may also disappear if the dose is reduced. 
Učinek lahko izgine tudi z zmanjšanjem odmerka.
Some of the undesirable effects will disappear without being treated but others may need medical attention. 
Nekateri neželeni učinki bodo izginili, ne da bi jih skušali odpraviti, pri drugih bo morda potrebna zdravniška pomoč.
• diuresis (increase in urination) 
• diureza (povečano izločanje urina),
Flushing of the face and hands has been noted. 
Opažena je bila rdečica na obrazu in dlaneh.
The duration of treatment depends on the indication for treatment and the patient´s response. 
Trajanje jemanja je odvisno od indikacije za zdravljenje in od bolnikovega odziva.
WHAT FORCALTONIN IS AND WHAT IT IS USED FOR 
KAJ JE FORCALTONIN IN ZA KAJ GA UPORABLJAMO
If you notice any unwanted effects not mentioned in this leaflet or any change in your health while receiving this medicine, or afterwards, please inform your doctor, nurse or pharmacist (chemist). 
Če opazite katerikoli neželen učinek, ki ni omenjen v tem navodilu, ali kakršnokoli spremembo v svojem zdravju med prejemanjem zdravila ali po njem, vas prosimo, da o tem obvestite svojega zdravnika, medicinsko sestro ali farmacevta (lekarnarja).
Use in elderly, hepatic and renal impairment patients Experience with the use of calcitonin in the elderly has shown no evidence of reduced tolerability or altered dosage requirements. 
Uporaba pri starejših bolnikih in bolnikih z okvaro jeter in ledvic Izkušnje z uporabo kalcitonina pri starejših niso pokazale znakov zmanjšane tolerance ali potreb po spreminjanju odmerkov.
Higher blood levels may be associated with increased incidence of nausea and vomiting. 
Višje koncentracije v krvi so lahko povezane s povečano pogostnostjo slabosti in bruhanja.
What FORCALTONIN is and what it is used for Before you use FORCALTONIN How to use FORCALTONIN Possible side effects 
Kaj je FORCALTONIN in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili FORCALTONIN Kako uporabljati FORCALTONIN Možni neželeni učinki
The dose may be reduced after the condition of the patient has improved. 
Odmerek lahko zmanjšamo, ko se bolnikovo stanje izboljša.